An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2.
Clin Microbiol Infect
; 30(8): 999-1006, 2024 Aug.
Article
em En
| MEDLINE
| ID: mdl-38663655
ABSTRACT
BACKGROUND:
Anti-spike monoclonal antibodies represent one of the most tolerable prophylaxis and therapies for COVID-19 in frail and immunocompromised patients. Unfortunately, viral evolution in Omicron has led all of them to failure.OBJECTIVES:
We review here the current pipeline of anti-spike mAb's, discussing in detail the most promising candidates. SOURCES We scanned PubMed, ClinicalTrials.gov and manufacturers' press releases for clinical studies on anti-spike monoclonal antibodies. CONTENT We present state-of-art data clinical progress for AstraZeneca's AZD3152, Invivyd's VYD222, Regeneron's REGN-17092 and Aerium Therapeutics' AER-800. IMPLICATIONS The anti-spike monoclonal antibody clinical pipeline is currently limited to few agents (most being single antibodies) with unknown efficacy against the dominant JN.1 sublineage. The field of antibody-based therapies requires boosting by both manufacturers and institutions.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Glicoproteína da Espícula de Coronavírus
/
SARS-CoV-2
/
Tratamento Farmacológico da COVID-19
/
Anticorpos Monoclonais
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article